HomeComparePHRRF vs GIS

PHRRF vs GIS: Dividend Comparison 2026

PHRRF yields 4155.41% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHRRF wins by $10365691035278.89M in total portfolio value
10 years
PHRRF
PHRRF
● Live price
4155.41%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10365691035278.97M
Annual income
$9,897,164,253,693,497,000.00
Full PHRRF calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — PHRRF vs GIS

📍 PHRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHRRFGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHRRF + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHRRF pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHRRF
Annual income on $10K today (after 15% tax)
$353,210.06/yr
After 10yr DRIP, annual income (after tax)
$8,412,589,615,639,472,000.00/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, PHRRF beats the other by $8,412,589,615,639,459,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHRRF + GIS for your $10,000?

PHRRF: 50%GIS: 50%
100% GIS50/50100% PHRRF
Portfolio after 10yr
$5182845517639.53M
Annual income
$4,948,582,126,846,757,000.00/yr
Blended yield
95.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

PHRRF
No analyst data
Altman Z
-14.2
Piotroski
1/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHRRF buys
0
GIS buys
0
No recent congressional trades found for PHRRF or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHRRFGIS
Forward yield4155.41%6.53%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$10365691035278.97M$78.8K
Annual income after 10y$9,897,164,253,693,497,000.00$16,211.26
Total dividends collected$10333779416010.36M$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PHRRF vs GIS ($10,000, DRIP)

YearPHRRF PortfolioPHRRF Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$426,241$415,541.24$11,502$801.73+$414.7KPHRRF
2$17,009,425$16,553,347.24$13,365$1,058.29+$17.00MPHRRF
3$635,556,863$617,356,778.09$15,712$1,411.34+$635.54MPHRRF
4$22,238,480,006$21,558,434,161.98$18,716$1,904.17+$22238.46MPHRRF
5$728,787,067,208$704,991,893,601.52$22,629$2,603.16+$728787.04MPHRRF
6$22,371,952,866,480$21,592,150,704,567.71$27,826$3,612.21+$22371952.84MPHRRF
7$643,400,978,312,961$619,462,988,745,827.60$34,871$5,097.54+$643400978.28MPHRRF
8$17,338,253,847,239,070$16,649,814,800,444,200.00$44,643$7,331.52+$17338253847.19MPHRRF
9$437,875,496,808,855,800$419,323,565,192,309,950.00$58,541$10,772.15+$437875496808.80MPHRRF
10$10,365,691,035,278,973,000$9,897,164,253,693,497,000.00$78,850$16,211.26+$10365691035278.89MPHRRF

PHRRF vs GIS: Complete Analysis 2026

PHRRFStock

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

Full PHRRF Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this PHRRF vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHRRF vs SCHDPHRRF vs JEPIPHRRF vs OPHRRF vs KOPHRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.